Pharmaceutical quality system guidelines in 2026 define GMP-based compliance expectations, focusing on inspection readiness, CAPA effectiveness, and data integrity. These frameworks support pharmaceutical organizations in building robust quality governance and risk-based quality management systems aligned with ICH Q10 principles.
